Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Compass Therapeutics

01/04/2025 15:07

** Shares of drug developer Compass Therapeutics CMPX.O fall 14.5% to $1.62

** CMPX says its experimental biliary tract cancer drug, tovecimig, when combined with chemotherapy, showed an overall response rate (ORR) of 17.1% in patients compared to 5.3% who received chemotherapy alone

** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined period of time

** Brokerage Leerink Partners says this response rate is lower than expected, and lower than what was seen in previous trials

** Other treatments, such as Enhertu by AstraZeneca AZN.L and Pemazyre by Incyte INCY.O, have shown higher response rates in similar patient populations, brokerage says

** Including sessions moves, CMPX stock up 31% YTD

(Reporting by Padmanabhan Ananthan)

((padmanabhan.ananthan@thomsonreuters.com))